Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Treatment of Erectile Disorder

  • Chapter
  • First Online:
The Textbook of Clinical Sexual Medicine

  • 2952 Accesses

Abstract

Erectile dysfunction (ED) is defined as the inability to achieve and/or maintain an erection sufficient to permit satisfactory sexual intercourse. ED may result from psychological, neurologic, hormonal, vascular, or impairment of cavernosal smooth muscle function. The last 3 decades have witnessed a phenomenal improvement in diagnosis and treatment of ED. In the current chapter we review contemporary medical and surgical treatments for ED and novel therapies in development.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ismail EA, El-Sakka AI. Innovative trends and perspectives for erectile dysfunction treatment: a systematic review. Arab J Urol. 2016;14:84–93.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Glina S, Sharlip ID, Hellstrom WJG. Modifying risk factors to prevent and treat erectile dysfunction. J Sex Med. 2013;10:115–9.

    Article  PubMed  Google Scholar 

  3. Esposito K, Ciotola M, Giugliano F, et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res. 2006;18:405–10.

    Article  CAS  PubMed  Google Scholar 

  4. Derby CA, Mohr BA, Goldstein I, et al. Modifable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 2000;56:302–6.

    Article  CAS  PubMed  Google Scholar 

  5. Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004;291:2978–84.

    Article  CAS  PubMed  Google Scholar 

  6. Bacon CG, Mittleman MA, Kawachi I, et al. A prospective study of risk factors for erectile dysfunction. J Urol. 2006;176:217–21.

    Article  PubMed  Google Scholar 

  7. Schrader SM, Breitenstein MJ, Lowe BD. Cutting off the nose to save the penis. J Sex Med. 2008;5:1932–40.

    Article  PubMed  Google Scholar 

  8. Ralph D, McNicholas T. UK management guidelines for erectile dysfunction. BMJ. 2000;321:499–503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med. 1991;114:613–20.

    Article  CAS  PubMed  Google Scholar 

  10. Grimm Jr RH, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension. 1997;29:8–14.

    Article  CAS  PubMed  Google Scholar 

  11. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995;75:191–236.

    CAS  PubMed  Google Scholar 

  12. Srilatha B, Adaikan PG, Arulkumaran S, et al. Sexual dysfunction related to antihypertensive agents: results from the animal model. Int J Impot Res. 1999;11:107–13.

    Article  CAS  PubMed  Google Scholar 

  13. Croog SH, Levine S, Sudilovsky A, et al. Sexual symptoms in hypertensive patients. A clinical trial of antihypertensive medications. Arch Intern Med. 1988;148:788–94.

    Article  CAS  PubMed  Google Scholar 

  14. Hannan JL, Smallegange C, Hale TM, et al. Impact of antihypertensive treatments on erectile responses in aging spontaneously hypertensive rats. J Hypertens. 2006;24:159–68.

    Article  CAS  PubMed  Google Scholar 

  15. Suzuki H, Tominaga T, Kumagai H, et al. Effects of frst-line antihypertensive agents on sexual function and sex hormones. J Hypertens Suppl. 1988;6:S649–51.

    Article  CAS  PubMed  Google Scholar 

  16. Cushman WC, Cohen JD, Jones RP, et al. Comparison of the fxed combination of enalapril/diltiazem ER and their monotherapies in stage 1 to 3 essential hypertension. Am J Hypertens. 1998;11:23–30.

    Article  CAS  PubMed  Google Scholar 

  17. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev. 2005;10:23–9.

    Article  CAS  PubMed  Google Scholar 

  18. Aizenberg D, Zemishlany Z, Dorfman-Etrog P, et al. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry. 1995;56:137–41.

    CAS  PubMed  Google Scholar 

  19. Wirshing DA, Pierre JM, Marder SR, et al. Sexual side effects of novel antipsychotic medications. Schizophr Res. 2002;56:25–30.

    Article  PubMed  Google Scholar 

  20. Keltner NL, Mcafee KM, Taylor CL. Mechanisms and treatments of SSRI induced sexual dysfunction. Perspect Psychiatr Care. 2002;38:111–6.

    Article  PubMed  Google Scholar 

  21. Gitlin MJ, Suri R, Altshuler L, et al. Bupropion-sustained release as a treatment for SSRIinduced sexual side effects. J Sex Marital Ther. 2002;28:131–8.

    Article  PubMed  Google Scholar 

  22. Kuba R, Pohanka M, Zakopcan J, et al. Sexual dysfunctions and blood men with focal epilepsy. Epilepsia. 2006;47:2135–40.

    Article  CAS  PubMed  Google Scholar 

  23. Gil-Nagel A, Lopez-Munoz F, Serratosa JM, et al. Effect of lamotrigine on sexual function in patients with epilepsy. Seizure. 2006;15:142–9.

    Article  CAS  PubMed  Google Scholar 

  24. Basaria S, Dobs AS. Hypogonadism and androgen replacement therapy in elderly men. Am J Med. 2001;110:563–72.

    Article  CAS  PubMed  Google Scholar 

  25. Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10:130–71.

    Article  CAS  PubMed  Google Scholar 

  26. Burnett AL. Phosphodiesterase 5 mechanisms and therapeutic applications. Am J Cardiol. 2005;96:M29–31.

    Article  CAS  Google Scholar 

  27. Khera M, Goldstein I. Erectile dysfunction. Clin Evid (Online) 2011; Jun 29:1803.

    Google Scholar 

  28. Shindel AW. 2009 update on phosphodiesterase type 5 inhibitor therapy, part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. J Sex Med. 2009;6:2352–64 .quiz 2365–6

    Article  CAS  PubMed  Google Scholar 

  29. Sadovsky R, Brock GB, Gutkin SW, et al. Toward a new “EPOCH”: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction. Int J Clin Pract. 2009;63:1214–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24:1601–10.

    Article  PubMed  Google Scholar 

  31. Jackson G, Montorsi P, Adams M, Anis T, El-Sakka A, Miner M, Vlachopoulos C, Kim E. Cardiovascular aspects of sexual medicine. J Sex Med. 2010;7:1608–26.

    Article  PubMed  Google Scholar 

  32. Carson CC, et al. The efficacy of sildenafil citrate (Viagra) in cli update. Urology. 2002;60(2 Suppl 2):12–27.

    Article  PubMed  Google Scholar 

  33. Kloner RA, et al. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens. 2001;14(1):70–3.

    Article  CAS  PubMed  Google Scholar 

  34. Lombardi G, et al. Ten-year follow-up of sildenafil use in spinal cord-injured patients with erectile dysfunction. J Sex Med. 2009;6(12):3449–57.

    Article  PubMed  Google Scholar 

  35. Seidman SN, et al. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry. 2001;158(10):1623–30.

    Article  CAS  PubMed  Google Scholar 

  36. Blander DS, et al. Efficacy of sildenafil in erectile dysfunction after radical prostatectomy. Int J Impot Res. 2000;12(3):165–8.

    Article  CAS  PubMed  Google Scholar 

  37. Rendell MS, et al. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA. 1999;281(5):421–6.

    Article  CAS  PubMed  Google Scholar 

  38. Wagner G, et al. Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol A Biol Sci Med Sci. 2001;56(2):M113–9.

    Article  CAS  PubMed  Google Scholar 

  39. Rajagopalan P, et al. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol. 2003;43(3):260–7.

    Article  CAS  PubMed  Google Scholar 

  40. Montorsi F, et al. Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebocontrolled trial. J Sex Med. 2004;1(2):168–78.

    Article  CAS  PubMed  Google Scholar 

  41. Forgue ST, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006;61(3):280–8.

    Article  CAS  PubMed  Google Scholar 

  42. Jung J, et al. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebocontrolled, dose-escalation study in healthy Korean male volunteers. Clin Ther. 2010;32(6):1178–87.

    Article  CAS  PubMed  Google Scholar 

  43. Kyle JA, Brown DA, Hill JK. Avanafil for erectile dysfunction. Ann Pharmacother. 2013;47(10):1312–20.

    Article  CAS  PubMed  Google Scholar 

  44. Cheitlin MD, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999;33(1):273–82.

    Article  CAS  PubMed  Google Scholar 

  45. Wang Z, Zhu D, Yang X, Li J, Jiang X, Tian G, et al. The selectivity and potency of the new PDE5 inhibitor TPN729MA. J Sex Med. 2013;10:2790–7.

    Article  CAS  PubMed  Google Scholar 

  46. Gao ZW, Zhu YT, Yu MM, Zan B, Liu J, Zhang YF, et al. Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model. Acta Pharmacol Sin. 2015;36:1528–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Ahn GJ, Chung HK, Lee CH, Kang KK, Ahn BO. Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical diabetogenesis. Asian J Androl. 2009;11:435–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Cho MC, Paick JS. A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction. Ther Adv Urol. 2016 Apr;8(2):100–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Kim E, Seftel A, Goldfischer E, Baygani S, Burns P. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil. Curr Med Res Opin. 2015;31:379–89.

    Article  CAS  PubMed  Google Scholar 

  50. Hatzichristou D, d’Anzeo G, Porst H, Buvat J, Henneges C, Rossi A, et al. Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities. BMC Urol. 2015;15:111.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Buvat J, Hatzichristou D, Boess FG, Büttner H, Gehchan N, Henneges C, et al. Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE study. Int J Clin Pract. 2014;68:1087–99.

    Article  CAS  PubMed  Google Scholar 

  52. Choi WS, Kwon OS, Cho SY, Paick JS, Kim SW. Effect of chronic administration of PDE5 combined with glycemic control on erectile function in streptozotocin-induced diabetic rats. J Sex Med. 2015;12:600–10.

    Article  CAS  PubMed  Google Scholar 

  53. Wessells H, Levine N, Hadley ME, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with melanotan II. Int J Impot Res. 2000;12(Suppl. 4):S74–9.

    Article  PubMed  Google Scholar 

  54. Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16:51–9.

    Article  CAS  PubMed  Google Scholar 

  55. Lal S, Rios O, Thavundayil JX. Treatment of impotence with trazodone: a case report. J Urol. 1990;143:819–20.

    CAS  PubMed  Google Scholar 

  56. Costabile RA, Spevak M. Oral trazodone is not effective therapy for erectile dysfunction: a double-blind, placebo controlled trial. J Urol. 1999;161:1819–22.

    Article  CAS  PubMed  Google Scholar 

  57. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol. 1998;159(2):433–6.

    Article  CAS  PubMed  Google Scholar 

  58. Heaton JP, et al. Recovery of erectile function by the oral administration of apomorphine. Urology. 1995;45(2):200–6.

    Article  CAS  PubMed  Google Scholar 

  59. Gwinup G. Oral phentolamine in nonspecific erectile insufficiency. Ann Intern Med. 1988;109(2):162–3.

    Article  CAS  PubMed  Google Scholar 

  60. Zorgniotti AW. Experience with buccal phentolamine mesylate for impotence. Int J Impot Res. 1994;6(1):37–41.

    CAS  PubMed  Google Scholar 

  61. Burnett AL. Oral pharmacotherapy for erectile dysfunction: current perspectives. Urology. 1999;54:392–400.

    Article  CAS  PubMed  Google Scholar 

  62. El-Sakka AI. What is the current role of intracavernosal injection in management of erectile dysfunction? Int J Impot Res. 2016;1–8.

    Google Scholar 

  63. Jeremy JY, et al. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol. 1997;79(6):958–63.

    Article  CAS  PubMed  Google Scholar 

  64. Stief CG, Wetterauer U. Erectile responses to intracavernous papaverine and phentolamine: comparison of single and combined delivery. J Urol. 1988;140(6):1415–6.

    CAS  PubMed  Google Scholar 

  65. Zorgniotti AW, Lefleur RS. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol. 1985;133:39–41.

    CAS  PubMed  Google Scholar 

  66. Bennett AH, Carpenter AJ, Barada JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol. 1991;146:1564–5.

    CAS  PubMed  Google Scholar 

  67. Floth A, Schramek P. Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone. J Urol. 1991;145:56–9.

    CAS  PubMed  Google Scholar 

  68. Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin North Am. 1995;22:833–45.

    CAS  PubMed  Google Scholar 

  69. Yilmaz D, Bayatli N, Un O, Kadowitz PJ, Sikka SC, Gur S. The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction. Urology. 2014;83:e7–e12.

    Article  Google Scholar 

  70. da Costa Gonçalves AC, Fraga-Silva RA, Leite R, Santos RA. AVE 0991, a nonpeptide Mas-receptor agonist, facilitates penile erection. Exp Physiol. 2013;98:850–5.

    Article  PubMed  CAS  Google Scholar 

  71. Lasker GF, Pankey EA, Allain AV, Dhaliwal JS, Stasch JP, Murthy SN, et al. Analysis of erectile responses to BAY 41-8543 and muscarinic receptor stimulation in the rat. J Sex Med. 2013;10:704–18.

    Article  CAS  PubMed  Google Scholar 

  72. Lasker GF, Pankey EA, Frink TJ, Zeitzer JR, Walter KA, Kadowitz PJ. The sGC activator BAY 60-2770 has potent erectile activity in the rat. Am J Physiol Heart Circ Physiol. 2013;304:H1670–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Nunes KP, Costa-Gonçalves A, Lanza LF, Cortes SF, Cordeiro MN, Richardson M, et al. Tx2-6 toxin of the Phoneutria nigriventer spider potentiates rat erectile function. Toxicon. 2008;51:1197–206.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Nunes KP, Toque HA, Borges MH, Richardson M, Webb RC, de Lima ME. Erectile function is improved in aged rats by PnTx2-6, a toxin from Phoneutria nigriventer spider venom. J Sex Med. 2012;9:2574–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Xie D, Pippen AM, Odronic SI, Annex BH, Donatucci CF. Intracavernosal basic fibroblast growth factor improves vasoreactivity in the hypercholesterolemic rabbit. J Sex Med. 2006;3:223–32.

    Article  CAS  PubMed  Google Scholar 

  76. Park K, Ahn KY, Kim MK, Lee SE, Kang TW, Ryu SB. Intracavernosal injection of vascular endothelial growth factor improves erectile function in aged rats. Eur Urol. 2004;46:403–7.

    Article  CAS  PubMed  Google Scholar 

  77. Gou X, He WY, Xiao MZ, Qiu M, Wang M, Deng YZ, et al. Transplantation of endothelial progenitor cells transfected with VEGF165 to restore erectile function in diabetic rats. Asian J Androl. 2011;13:332–8.

    Article  CAS  PubMed  Google Scholar 

  78. Lasker GF, Matt CJ, Badejo Jr AM, Casey DB, Dhaliwal JS, Murthy SN, et al. Intracavernosal administration of sodium nitrite as an erectile pharmacotherapy. Can J Physiol Pharmacol. 2010;88:770–6.

    Article  CAS  PubMed  Google Scholar 

  79. Soebadi MA, Moris L, Castiglione F, Weyne E, Albersen M. Advances in stem cell research for the treatment of male sexual dysfunctions. Curr Opin Urol. 2016;26:129–39.

    Article  PubMed  Google Scholar 

  80. Sung HH, Ahn JS, Kim JJ, Choo SH, Han DH, Lee SW. The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors. Andrology. 2014;2:45–50.

    Article  CAS  PubMed  Google Scholar 

  81. Nelson CJ, Hsiao W, Balk E, Narus J, Tal R, Bennett NE, et al. Injection anxiety and pain in men using intracavernosal injection therapy after radical pelvicsurgery. J Sex Med. 2013;10:2559–65.

    Article  PubMed  Google Scholar 

  82. Mulhall JP, Simmons J. Assessment of comparative treatment satisfaction with sildenafil citrate and penile injection therapy in patients responding to both. BJU Int. 2007;100:1313–6.

    Article  PubMed  Google Scholar 

  83. Kim SC, Chang IH, Jeon HJ. Preference for oral sildenafil or intracavernosal injection in patients with erectile dysfunction already using intracavernosal injection for 41 year. BJU Int. 2003;92:277–80.

    Article  CAS  PubMed  Google Scholar 

  84. El-Sakka AI. Intracavernosal prostaglandin E1 self-versus office injection therapy in patients with erectile dysfunction. Int J Impot Res. 2006;18:180–5.

    Article  CAS  PubMed  Google Scholar 

  85. Sharlip ID. Evaluation and nonsurgical management of erectile dysfunction. Urol Clin North Am. 1998;25:647–59.

    Article  CAS  PubMed  Google Scholar 

  86. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997;336:1–7.

    Article  CAS  PubMed  Google Scholar 

  87. Guay AT, Perez JB, Velásquez E, et al. Clinical experience with intraurethral alprostadil (MUSE) in the treatment of men with erectile dysfunction. A retrospective study: medicated urethral system for erection. Eur Urol. 2000;38:671–6.

    Article  CAS  PubMed  Google Scholar 

  88. Zippe CD, et al. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology. 1998;52(6):963–6.

    Article  CAS  PubMed  Google Scholar 

  89. Padma-Nathan H. Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. Am J Cardiol. 2003;92(9A):19M–25M.

    Article  CAS  PubMed  Google Scholar 

  90. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen defciency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536–59.

    Article  CAS  PubMed  Google Scholar 

  91. Bagatell CJ, Bremner WJ. Androgens in men—uses and abuses. N Engl J Med. 1996;334:707–14.

    Article  CAS  PubMed  Google Scholar 

  92. Kunelius P, Lukkarinen O, Hannuksela ML, et al. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab. 2002;87:1467–72.

    Article  CAS  PubMed  Google Scholar 

  93. Morales A, Buvat J, Gooren LJ, et al. Endocrine aspects of sexual dysfunction in men. J Sex Med. 2004;1:69–81.

    Article  CAS  PubMed  Google Scholar 

  94. Tsujimura A, Matsumiya K, Takao T, et al. Treatment with human chorionic gonadotropin for PADAM: a preliminary report. Aging Male. 2005;8:175–9.

    Article  CAS  PubMed  Google Scholar 

  95. Wang C, Nieschlag E, Swerdloff R, International Society of Andrology (ISA), International Society for the Study of Aging Male (ISSAM), European Association of Urology (EAU), European Academy of Andrology (EAA), American Society of Andrology (ASA), et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl. 2009;30:1–9.

    Article  PubMed  Google Scholar 

  96. Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485–534.

    Article  CAS  PubMed  Google Scholar 

  97. Netto Júnior NR, Claro JA. The importance of hyperprolactinemia in impotence. Rev Paul Med. 1993;111:454–5.

    PubMed  Google Scholar 

  98. Estancial CS, Rodrigues RL, De Nucci G, Antunes E, Mónica FZ. Pharmacological characterisation of the relaxation induced by the soluble guanylate cyclase activator, BAY 60-2770 in rabbit corpus cavernosum. BJU Int. 2015;116:657–64.

    Article  CAS  PubMed  Google Scholar 

  99. Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006;5:755–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Claudino MA, da Silva FH, Mónica FZ, Rojas-Moscoso JA, De Nucci G, Antunes E. Long-term oral treatment with BAY 41–2272 ameliorates impaired corpus cavernosum relaxations in a nitric oxide-deficient rat model. BJU Int. 2011;108:116–22.

    Article  CAS  PubMed  Google Scholar 

  101. Oudot A, Behr-Roussel D, Poirier S, Sandner P, Bernabé J, Alexandre L, Giuliano F. Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. Eur Urol. 2011;60(5):1020–6.

    Article  CAS  PubMed  Google Scholar 

  102. Levy JA, Marchand M, Iorio L, Cassini W, Zahalsky MP. Determining the feasibility of managing erectile dysfunction in humans with placental-derived stem cells. J Am Osteopath Assoc. 2016;116:e1–5.

    Article  PubMed  Google Scholar 

  103. Yang R, Fang F, Wang J, Guo H. Adipose-derived stem cells ameliorate erectile dysfunction after cavernous nerve cryoinjury. Andrology. 2015;3:694–701.

    Article  CAS  PubMed  Google Scholar 

  104. Yiou R, Hamidou L, Birebent B, Bitari D, Lecorvoisier P, Contremoulins I, et al. Safety of intracavernous bone marrow mononuclear cells for postradical prostatectomy erectile dysfunction: an open doseescalation pilot study. Eur Urol. 2015;. 10.1016/j.eururo.2015.09.026 [Epub ahead of print].

  105. Gokce A, Abd Elmageed ZY, Lasker GF, Bouljihad M, Braun H, Kim H, et al. Intratunical injection of genetically modified adipose tissue-derived stem cells with human interferon a 2b for treatment of erectile dysfunction in a rat model of tunica albugineal fibrosis. J Sex Med. 2015;12:1533–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Song L, Zhu J, Zhang X, Cui Z, Fu Q, Huang J, et al. BDNFhypersecreting human umbilical cord blood mesenchymal stem cells promote erectile function in a rat model of cavernous nerve electrocautery injury. Int Urol Nephrol. 2016;48:37–45.

    Article  CAS  PubMed  Google Scholar 

  107. Liu T, Peng Y, Jia C, Fang X, Li J, Zhong W. Hepatocyte growth factor-modified adipose tissue-derived stem cells improve erectile function in streptozotocin-induced diabetic rats. Growth Factors. 2015;33(4):282–9.

    Article  CAS  PubMed  Google Scholar 

  108. Jeon SH, Shrestha KR, Kim RY, Jung AR, Park YH, Kwon O, et al. Combination therapy using human adipose-derived stem cells on the cavernous nerve and low-energy shockwaves on the corpus cavernosum in a rat model of post-prostatectomy erectile dysfunction. Urology. 2016;88(226):e1–9.

    Google Scholar 

  109. Vardi Y, Appel B, Kilchevsky A, Gruenwald I. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, doubleblind, sham controlled study. J Urol. 2012;187:1769–75.

    Article  PubMed  Google Scholar 

  110. Young S, Dyson M. The effect of therapeutic ultrasound on angiogenesis. Ultrasound Med Biol. 1990;16:261–9.

    Article  CAS  PubMed  Google Scholar 

  111. Qiu X, Lin G, Xin Z, Ferretti L, Zhang H, Lue T, et al. Effects of low-energy shockwave therapy on the erectile function and tissue of a diabetic rat model. J Sex Med. 2013;10:738–46.

    Article  CAS  PubMed  Google Scholar 

  112. Frey A, Sønksen J, Fode M. Low-intensity extracorporeal shockwave therapy in the treatment of postprostatectomy erectile dysfunction: a pilot study. Scand J Urol. 2016;50:123–7.

    Article  PubMed  Google Scholar 

  113. Liu J, Zhou F, Li GY, Wang L, Li HX, Bai GY, et al. Evaluation of the effect of different doses of low energy shock wave therapy on the erectile function of streptozotocin (STZ)-induced diabetic rats. Int J Mol Sci. 2013;14:10661–73.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Abu-Ghanem Y, Kitrey ND, Gruenwald I, Appel B, Vardi Y. Penile low-intensity shock wave therapy: a promising novel modality for erectile dysfunction. Korean J Urol. 2014;55:295–9.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Shin YS, Zhao C, Zhang LT, Park JK. Current status and clinical studies of oriental herbs in sexual medicine in Korea. World J Mens Health. 2015;33:62–72.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Ferrini MG, Hlaing SM, Chan A, Artaza JN. Treatment with a combination of ginger, L-citrulline, muira puama and Paullinia cupana can reverse the progression of corporal smooth muscle loss, fibrosis and veno-occlusive dysfunction in the aging rat. Androl Open Access. 2015;4(1). pii: 131.

    Google Scholar 

  117. Ayuob NN, Al-Harbi MS, Abdulhadi SS. Is the chronic use of Ferula harmonis to enhance mice erectile function effective and safe? A histopathological study. Syst Biol Reprod Med. 2014;60:282–92.

    Article  PubMed  Google Scholar 

  118. Pavan V, Mucignat-Caretta C, Redaelli M, Ribaudo G, Zagotto G. The old made new: natural compounds against erectile dysfunction. Arch Pharm (Weinheim). 2015;348:607–14.

    Article  CAS  Google Scholar 

  119. Kotirum S, Ismail SB, Chaiyakunapruk N. Efficacy of Tongkat Ali (Eurycoma longifolia) on erectile function improvement: systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2015;23:693–8.

    Article  PubMed  Google Scholar 

  120. Bai Y, An R. Resveratrol and sildenafil synergistically improve diabetes associated erectile dysfunction in streptozotocin-induced diabetic rats. Life Sci. 2015;135:43–8.

    Article  CAS  PubMed  Google Scholar 

  121. Sawant SD, Lakshma Reddy G, Dar MI, Srinivas M, Gupta G, Sahu PK, et al. Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5. Bioorg Med Chem. 2015;23:2121–8.

    Article  CAS  PubMed  Google Scholar 

  122. Nishimatsu H, Suzuki E, Saito Y, Niimi A, Nomiya A, Yamada D, et al. Neuromedin B restores erectile function by protecting the cavernous body and the nitrergic nerves from injury in a diabetic rat model. PLoS ONE. 2015;10:e0133874.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  123. Owen JA, Saunders F, Harris C, et al. Topical nitroglycerin: a potential treatment for impotence. J Urol. 1989;141:546–8.

    CAS  PubMed  Google Scholar 

  124. Kim ED, el Rashidy R, McVary KT. Papaverine topical gel for treatment oferectile dysfunction. J Urol. 1995;153:361–5.

    Article  CAS  PubMed  Google Scholar 

  125. Schanz S, Hauck EW, Schmelz HU, et al. Topical treatment of erectile dysfunction with prostaglandin E ethyl ester. J Dtsch Dermatol Ges. 2009;7:1055–9.

    PubMed  Google Scholar 

  126. Everaert K, de Waard W, Van Hoof T, Kiekens C, Mulliez T, D’Herde C. Neuroanatomy and neurophysiology related to sexual dysfunction in male neurogenic patients with lesions tothe spinal cord or peripheral nerves. Spinal Cord. 2010;48:182–91.

    Article  CAS  PubMed  Google Scholar 

  127. Tajkarimi K, Burnett A. Viberect device use by men with erectile dysfunction: safety, ease of use, tolerability, and satisfaction survey. J Sex Med 2011; 8(Suppl), 441–441.

    Google Scholar 

  128. Shafik A, El-Sibai O, Shafik A. Magnetic stimulation of the cavernous nerve for the treatment of erectile dysfunction in humans. Int J Impot Res. 2000;12:137–42.

    Article  CAS  PubMed  Google Scholar 

  129. Yoo J, Park H, Lee I, Atala A. Autologous engineered cartilage rods for penile reconstruction. J Urol. 1999;162:1119–21.

    Article  CAS  PubMed  Google Scholar 

  130. Kershen R, Yoo J, Moreland R, Krane R, Atala A. Reconstitution of human corpus cavernosum smooth muscle in vitro and in vivo. Tissue Eng. 2002;8:515–24.

    Article  PubMed  Google Scholar 

  131. Chen K, Eberli D, Yoo J, Atala A. Bioengineered corporal tissue for structural and functional restoration of the penis. Proc Natl Acad Sci U S A. 2010;107:3346–50.

    Article  CAS  PubMed  Google Scholar 

  132. Han G, Tar M, Kuppam D, Friedman A, Melman A, Friedman J, et al. Nanoparticles as a novel delivery vehicle for therapeutics targeting erectile dysfunction. J Sex Med. 2010;7:224–33.

    Article  CAS  PubMed  Google Scholar 

  133. Lin H, Dhanani N, Tseng H, Souza GR, Wang G, Cao Y, et al. Nanoparticle improved stem cell therapy for erectile dysfunction in a rat model of cavernous nerve injury. J Urol. 2016;195:788–95.

    Article  CAS  PubMed  Google Scholar 

  134. Rogers JH, Goldstein I, Kandzari DE, Köhler TS, Stinis CT, Wagner PJ, et al. Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors. J Am Coll Cardiol. 2012;60:2618–27.

    Article  CAS  PubMed  Google Scholar 

  135. Babaev A, Jhaveri R. Angiography and endovascular revascularization of pudendal artery atherosclerotic disease in patients with medically refractory erectile dysfunction. J Invasive Cardiol. 2012;24:236–40.

    PubMed  Google Scholar 

  136. Herwig R, Sansalone S. Venous leakage treatment revisited: pelvic venoablation using aethoxysclerol under air block technique and Valsalva maneuver. Arch Ital Urol Androl. 2015;87:1–4.

    Article  PubMed  Google Scholar 

  137. Aschenbach R, Steiner T, Kerl M, Zangos S, Basche S, Vogl T. Endovascular embolisation therapy in men with erectile impotence due to veno-occlusive dysfunction. Eur J Radiol. 2013;82:504–7.

    Article  CAS  PubMed  Google Scholar 

  138. Chen J, Godschalk MF, Katz PG, et al. Combining intracavernous injection and external vacuum as treatment for erectile dysfunction. J Urol. 1995;153:1476–7.

    Article  CAS  PubMed  Google Scholar 

  139. John H, Lehmann K, Hauri D. Intraurethral prostaglandin improves quality of vacuum erection therapy. Eur Urol. 1996;29:224–6.

    CAS  PubMed  Google Scholar 

  140. McMahon CG, Samali R, Johnson H. Treatment of intracorporeal injection nonresponse with sildenafl alone or in combination with triple agent intracorporeal injection therapy. J Urol. 1999;162:1992–7.

    Article  CAS  PubMed  Google Scholar 

  141. Benevides MD, Carson CC. Intraurethral application of alprostadil in patients with failed inflatable penile prosthesis. J Urol. 2000;163:785–7.

    Article  CAS  PubMed  Google Scholar 

  142. Nehra A, Blute ML, Barrett DM, et al. Rationale for combination therapy of intraurethral prostaglandin E (1) and sildenafl in the salvage of erectile dysfunction patients desiring noninvasive therapy. Int J Impot Res. 2002;14(Suppl. 1):S38–42.

    Article  PubMed  Google Scholar 

  143. Shabsigh R, Kaufman JM, Steidle C, et al. Randomized study of testosterone gel as adjunctive therapy to sildenafl in hypogonadal men with erectile dysfunction who do not respond to sildenafl alone. J Urol. 2004;172:658–63.

    Article  CAS  PubMed  Google Scholar 

  144. Althof SE, Leiblum SR, Chevret-Measson M, et al. Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med. 2005;2:793–800.

    Article  PubMed  Google Scholar 

  145. Canguven O, Bailen J, Fredriksson W, et al. Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction. J Sex Med. 2009;6:2561–7.

    Article  PubMed  Google Scholar 

  146. Wooten JS. Ligation of the dorsal vein of the penis as a cure for atonic impotence. Texas Med J. 1902;18:325–7.

    Google Scholar 

  147. Virag R, et al. Investigation and surgical treatment of vasculogenic impotency (author’s transl). J Mal Vasc. 1980;5(3):205–9.

    CAS  PubMed  Google Scholar 

  148. Breza J, et al. Cavernous vein arterialization for vasculogenic impotence. An animal model. Urology. 1990;35(6):513–8.

    Article  CAS  PubMed  Google Scholar 

  149. Goldstein I. Overview of types and results of vascular surgical procedures for impotence. Cardiovasc Intervent Radiol. 1988;11(4):240–4.

    Article  CAS  PubMed  Google Scholar 

  150. Hauri D. Penile revascularization surgery in erectile dysfunction. Urol Int. 2003;70(2):132–40.

    Article  CAS  PubMed  Google Scholar 

  151. Zumbe J, et al. Indications for penile revascularization and long-term results. Andrologia. 1999;31(Suppl 1):83–7.

    PubMed  Google Scholar 

  152. Goldstein I. Arterial revascularization procedures. Semin Urol. 1986;4(4):252–8.

    CAS  PubMed  Google Scholar 

  153. Lund GO, Winfield HN, Donovan JF. Laparoscopically assisted penile revascularization for vasculogenic impotence. J Urol. 1995;153(6):1923–6.

    Article  CAS  PubMed  Google Scholar 

  154. Benson CB, Vickers MA. Sexual impotence caused by vascular disease: diagnosis with duplex sonography. AJR Am J Roentgenol. 1989;153(6):1149–53.

    Article  CAS  PubMed  Google Scholar 

  155. Delcour C, et al. Impotence: evaluation with cavernosography. Radiology. 1986;161(3):803–6.

    Article  CAS  PubMed  Google Scholar 

  156. Kim ED, McVary KT. Long-term results with penile vein ligation for venogenic impotence. J Urol. 1995;153(3 Pt 1):655–8.

    Article  CAS  PubMed  Google Scholar 

  157. Motiwala HG, et al. Experience with penile venous surgery. Urol Int. 1993;51(1):9–14.

    Article  CAS  PubMed  Google Scholar 

  158. Small MP, Carrion HM, Gordon JA. Small-Carrion penile prosthesis: new implant for management of impotence. Urology. 1975;5(4):479–86.

    Article  CAS  PubMed  Google Scholar 

  159. Mulcahy JJ, et al. The penile implant for erectile dysfunction. J Sex Med. 2004;1(1):98–109.

    Article  PubMed  Google Scholar 

  160. Rajpurkar A, Dhabuwala CB. Comparison of satisfaction rates and erectile function in patients treated with sildenafl, intracavernous prostaglandin E1 and penile implant surgery for erectile dysfunction in urology practice. J Urol. 2003;170(1):159–63.

    Article  CAS  PubMed  Google Scholar 

  161. Al-Enezi A, Al-Khadhari S, Al-Shaiji TF. Three-piece inflatable penile prosthesis: surgical techniques and pitfalls. J Surg Tech Case Rep. 2011;3(2):76–83.

    Article  PubMed  PubMed Central  Google Scholar 

  162. Montague DK. Penile prosthesis implantation in the era of medical treatment for erectile dysfunction. Urol Clin North Am. 2011;38(2):217–25.

    Article  PubMed  Google Scholar 

  163. Mulcahy JJ, Wilson SK. Current use of penile implants in erectile dysfunction. Curr Urol Rep. 2006;7(6):485–9.

    Article  PubMed  Google Scholar 

  164. Ji YS, Ko YH, Song PH, Moon KH. Long-term survival and patient satisfaction with inflatable penile prosthesis for the treatment of erectile dysfunction. Korean J Urol. 2015 Jun;56(6):461–5.

    Article  PubMed  PubMed Central  Google Scholar 

  165. Kramer Akin-Olugbade O, Parker M, Guhring P, et al. Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med. 2006;3(4):743–8.

    Article  Google Scholar 

  166. Akin-Olugbade O, Parker M, Guhring P, et al. Determinants of patient satisfaction following penile prosthesis surgery. J Sex Med. 2006;3(4):743–8.

    Article  PubMed  Google Scholar 

  167. Lee K, Brock G. Strategies for maintaining penile size following penile implant. Transl Androl Urol. 2013;2(1):67–73.

    PubMed  PubMed Central  Google Scholar 

  168. Henry GD, Wilson SK, Delk 2nd JR, et al. Penile prosthesis cultures during revision surgery: a multicenter study. J Urol. 2004;172(1):153–6.

    Article  PubMed  Google Scholar 

  169. Wilson SK, Mulcahy JJ. Penile implants. In: Mulcahy J, editor. Male sexual function: a guide to clinical management. 2nd ed. Jersey City, NJ: Humana; 2006. p. 331–79.

    Chapter  Google Scholar 

  170. Bettocchi C, Palumbo F, Spilotros M, et al. Penile prostheses. Ther Adv Urol. 2010;2(1):35–40.

    Article  PubMed  PubMed Central  Google Scholar 

  171. Wilson SK, Henry GD, Delk Jr JR, et al. The mentor alpha 1 penile prosthesis with reservoir lock-out valve: effective prevention of auto-inflation with improved capability for ectopic reservoir placement. J Urol. 2002;168(4 Pt 1):1475–8.

    Article  PubMed  Google Scholar 

  172. El-Sakka AI, Yassin AA. Amelioration of penile fibrosis: myth or reality. J Androl. 2010;31:324–35.

    Article  CAS  PubMed  Google Scholar 

  173. El-Sakka AI. Alleviation of post-radical prostatectomy cavernosal fibrosis: future directions and potential utility for PDE5 inhibitors. Expert Opin Investig Drugs. 2011;20(10):1305–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Suez Canal University, School of Medicine, Ismailia, Egypt

    Ezzat A. Ismail & Ahmed I. El-Sakka

Authors
  1. Ezzat A. Ismail
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmed I. El-Sakka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmed I. El-Sakka .

Editor information

Editors and Affiliations

  1. Cedars-Sinai Department of Psychiatry and Behavioral Neurosciences, Cedars-Sinai Medical Center, Los Angeles, California, USA

    Waguih William IsHak

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Ismail, E.A., El-Sakka, A.I. (2017). Treatment of Erectile Disorder. In: IsHak, W. (eds) The Textbook of Clinical Sexual Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-52539-6_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-52539-6_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-52538-9

  • Online ISBN: 978-3-319-52539-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation